Loading…
← CockpitCompetitor Analysis › DMAC DiaMedica Therapeutics Inc.Open in the cockpit ↗

DiaMedica Therapeutics Inc.DMACCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum leader 94
Mkt cap
$463M
US dollars, full cap
Free float
57%
of shares outstanding
$/day
$2.05M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 9.8%
Hurdle
n/a
no reverse DCF
Next earnings
125 days
23 Mar 2027
Close · USD$8.59
1D+2.5%
1W-11.1%
1M-0.9%
3M+31.8%
6M+50.2%
YTD+7.9%
1Y+34.0%
ATR %8.1%
Beta1.76
52w lowhigh21.9% off high

What DiaMedica Therapeutics does

Employees: 35

DiaMedica Therapeutics at a glance

Size DiaMedica Therapeutics (DMAC) is a United States Health Care company (Biotechnology) with a market value of $463M, the 2735th largest of 3,085 United States companies the cockpit tracks. Shares closed at $8.59 on 18 Nov 2026.

Performance Over six months the shares gained 50.2%, against -8.0% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 19 in its peer set.

Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026DMAC 149Peer median 91
Six months, rebased to 100: DiaMedica Therapeutics against the median of its 20 peers (local-currency closes).

DiaMedica Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$46,000-$43,000-$39,000-$30,000-$25,000
EBITDA-$41.8M-$34.4M-$26.6M-$21.2M-$14.0M
Net income-$40.2M-$32.8M-$24.4M-$19.4M-$13.7M
Free cash flow-$33.7M-$29.5M-$22.1M-$18.8M-$11.6M
Capital expenditure$26,343$40,000$25,000$24,000$81,000
Total debt$157,000$240,000$340,000$400,000$469,000

Quarterly statements and history in the cockpit →

DiaMedica Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%KMDAFENCSTTK041960115180NGNEMNPR4147CBIOARVN6586IRLA000710DMAC6-month return →1-month return →
Up and to the right = strong over both horizons. DiaMedica Therapeutics is the large dot.

DiaMedica Therapeutics competitors and peer comparison

How DiaMedica Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

DiaMedica Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureDMACPeer medianRank in peer set
1-month return-0.9%-10.3%6th highest of 21
6-month return+50.2%-8.0%2nd highest of 19
Distance from 52-week high-21.9%-41.1%4th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
DiaMedica Therapeutics DMACUnited States$463M+50%n/an/an/an/an/a
HanchorBio 7827.TWTaiwan$462Mn/an/a-4,673%509.6×n/an/a
Kamada KMDAUnited States$465M+3%+5%15%2.0×5.0%+6.5%
TenNor Therapeutics Suzhou 6872.HKHong Kong$470Mn/an/an/an/an/an/a
Fennec Pharmaceuticals FENCUnited States$471M+37%+71%5%6.4×58.8%+204.7%
Shattuck Labs STTKUnited States$455M-28%-100%n/an/an/an/a
Komipharm International 041960.KSSouth Korea$454M-2%-6%-1%11.8×n/an/a
Qurient 115180.KSSouth Korea$452M-56%-14%-512%84.4×n/an/a
Neurogene NGNEUnited States$479M-14%-100%n/an/an/an/a
Monopar Therapeutics MNPRUnited States$479M+9%n/an/an/an/an/a
TaiMed Biologics 4147.TWOTaiwan$480M+19%+7%-31%22.7×n/an/a
Crescent Biopharma CBIOUnited States$482M-34%n/a-1,217%13.3×n/an/a
EirGenix 6589.TWTaiwan$444M+15%+58%-51%9.9×n/an/a
Arvinas ARVNUnited States$443M-26%-12%-10%n/an/an/a
CHO Pharma 6586.TWOTaiwan$488M+24%-47%-17,694%8,281.1×n/an/a
IRulya Therapeutics IRLAUnited States$440M+88%n/an/an/an/an/a
Berry Genomics 000710.SZChina$439M-17%-2%-24%3.3×n/an/a
Liaoning Dingjide Petrochemical 603255.SSChina$490M-24%+70%5%5.2×n/an/a
Qingdao Vland Biotech 603739.SSChina$437M-24%+5%7%2.2×7.7%+7.3%
Sinotherapeutics 688247.SSChina$494M-19%-17%0%6.2×29.4%+7.0%
Scinopharm Taiwan 1789.TWTaiwan$435M-2%-5%-4%4.0×2.1%+0.5%

Questions

Which companies are DiaMedica Therapeutics's closest peers?
The cockpit's peer set: HanchorBio (7827.TW), Kamada (KMDA), TenNor Therapeutics Suzhou (6872.HK), Fennec Pharmaceuticals (FENC), Shattuck Labs (STTK), Komipharm International (041960.KS), Qurient (115180.KS), Neurogene (NGNE).
How has DiaMedica Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned +50.2% against -8.0% for the median peer; over one year +34.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.